Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models
1. 系统已在2025-10-07 10:18:00对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: https://doi.org/10.1021/acs.jmedchem.0c00369
文献链接: https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00369
其他信息:
出版社: American Chemical Society (ACS)
作者: Ulrich Lücking; Lars Wortmann; Antje M. Wengner; Julien Lefranc; Philip Lienau; Hans Briem; Gerhard Siemeister; Ulf Bömer; Karsten Denner; Martina Schäfer; Marcus Koppitz; Knut Eis; Florian Bartels; Benjamin Bader; Wilhelm Bone; Dieter Moosmayer; Simon J. Holton; Uwe Eberspächer; Joanna Grudzinska-Goebel; Christoph Schatz; Gesa Deeg; Dominik Mumberg; Franz von Nussbaum
